ViiV & our PrEP patent application: ViiV: C
Post# of 151786
(Total Views: 480)
Posted On: 02/20/2025 7:10:15 PM
ViiV & our PrEP patent application:
ViiV:
Cabotegravir is the only long-acting PrEP available now
WHO:
Cabotegravir can cause MDR for PrEP people.
Cytodyn recent PrEP patent application:
[0006]:
Similarly, use of ART in HIV-negative individuals as PrEP results in unwanted side effects that reduce adherence. Therefore, the development of new user-friendly PrEP and HIV suppression regimens, particularly with simplified dosing regimens that lack unwanted negative side effects, is an urgent global health need.
patentguru.com/assignee/cyt...
The iP value of our Hiv portfolio keeps going up & up.
BOOOM !!!
ViiV:
Cabotegravir is the only long-acting PrEP available now
WHO:
Cabotegravir can cause MDR for PrEP people.
Cytodyn recent PrEP patent application:
[0006]:
Similarly, use of ART in HIV-negative individuals as PrEP results in unwanted side effects that reduce adherence. Therefore, the development of new user-friendly PrEP and HIV suppression regimens, particularly with simplified dosing regimens that lack unwanted negative side effects, is an urgent global health need.
patentguru.com/assignee/cyt...
The iP value of our Hiv portfolio keeps going up & up.
BOOOM !!!
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼